Open Access

Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer

  • Authors:
    • Min Wang
    • Jing Wang
    • Honggang Jiang
  • View Affiliations

  • Published online on: January 22, 2019     https://doi.org/10.3892/ol.2019.9957
  • Pages: 3227-3232
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diagnostic value of apolipoprotein C‑I (ApoC‑I), transthyretin (TTR) and ApoC‑III in gastric cancer were evaluated. Retrospective analysis methods were used to collect 60 patients with gastric cancer first diagnosed in The First Affiliated Hospital of Jiaxing University. There were 60 patients with chronic atrophic gastritis in the benign lesion group and 60 healthy individuals in the control group. The expression levels of serum ApoC‑I, TTR and ApoC‑III was detected by enzyme‑linked immunosorbent assay. Differences existed in the expression levels of ApoC‑I, TTR and ApoC‑III in the gastric cancer group, benign lesion group and control group (P<0.001), with the expression levels of ApoC‑I, TTR and ApoC‑III in the gastric cancer group being lower than that of the benign lesion group (P<0.05), and the expression levels of ApoC‑I, TTR and ApoC‑III in the benign lesion group being lower than that of the control group (P<0.05). The expression levels of ApoC‑I, TTR and ApoC‑III in the gastric cancer group were to a certain degree correlated with the clinical stage, lymph node metastasis and differentiation of patients in the gastric cancer group (P<0.05). The specificity and negative predictive value of combined detection were proven to be higher than the separate detection of the three factors (P<0.05). The detection of serum ApoC‑I, TTR and ApoC‑III was of great significance in the diagnosis of gastric cancer and the estimation of its severity. The method of combined detection is worth a further in‑depth study as it could improve the specificity of diagnosis and have a higher negative predictive value.

References

1 

Liu X, Li Z, Song Y, Wang R, Han L, Wang Q, Jiang K, Kang C and Zhang Q: AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer. Oncotarget. 7:33152–33164. 2016.PubMed/NCBI

2 

Yoon H and Kim N: Diagnosis and management of high risk group for gastric cancer. Gut Liver. 9:5–17. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Takatsu Y, Hiki N, Nunobe S, Ohashi M, Honda M, Yamaguchi T, Nakajima T and Sano T: Clinicopathological features of gastric cancer in young patients. Gastric Cancer. 19:472–478. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Shimada H, Noie T, Ohashi M, Oba K and Takahashi Y: Clinical significance of serum tumor markers for gastric cancer: A systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Wang C, Zhang J, Cai M, Zhu Z, Gu W, Yu Y and Zhang X: DBGC: A database of human gastric cancer. PLoS One. 10:e01425912015. View Article : Google Scholar : PubMed/NCBI

6 

Kim T, Chung H, Yu W, Kim JY, Kim GC and Choi J: Localization of gastric cancer by CT gastrography: A prospective study. Hepatogastroenterology. 56:1580–1584. 2009.PubMed/NCBI

7 

Yanai H, Matsubara Y, Kawano T, Okamoto T, Hirano A, Nakamura Y, Nakamura H, Nishikawa J and Okita K: Clinical impact of strip biopsy for early gastric cancer. Gastrointest Endosc. 60:771–777. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Kanda M and Kodera Y: Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 21:9838–9852. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB and Yan C: Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: A Systematic Review and Meta-Analysis. PLoS One. 10:e01420802015. View Article : Google Scholar : PubMed/NCBI

10 

Shin VY, Ng EK, Chan VW, Kwong A and Chu KM: A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Mol Cancer. 14:2022015. View Article : Google Scholar : PubMed/NCBI

11 

Song D, Yue L, Zhang J, Ma S, Zhao W, Guo F, Fan Y, Yang H, Liu Q, Zhang D, et al: Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry. Cancer Biol Ther. 17:635–647. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Wang X, Han J, Hardie DB, Yang J and Borchers CH: The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers. J Mass Spectrom. 51:86–95. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Shi J, Yang H, Duan X, Li L, Sun L, Li Q and Zhang J: Apolipoproteins as differentiating and predictive markers for assessing clinical outcomes in patients with small cell lung cancer. Yonsei Med J. 57:549–556. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Cohen M, Yossef R, Erez T, Kugel A, Welt M, Karpasas MM, Bones J, Rudd PM, Taieb J, Boissin H, et al: Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: Results from MALDI-based peptidome and immuno-based clinical assays. PLoS One. 6:e145402011. View Article : Google Scholar : PubMed/NCBI

15 

Vieira M and Saraiva MJ: Transthyretin: A multifaceted protein. Biomol Concepts. 5:45–54. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Fentz AK, Spörl M, Spangenberg J, List HJ, Zornig C, Dörner A, Layer P, Juhl H and David KA: Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels. Proteomics Clin Appl. 1:536–544. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Helgason HH, Engwegen JY, Zapatka M, Vincent A, Cats A, Boot H, Beijnen JH and Schellens JH: Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncol Rep. 24:57–64. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Choi BW, Kim HW, Won KS, Song BI, Cho KB and Bae SU: Diagnostic accuracy of 18F-FDG PET/CT for detecting synchronous advanced colorectal neoplasia in patients with gastric cancer. Medicine (Baltimore). 95:e47412016. View Article : Google Scholar : PubMed/NCBI

19 

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 Suppl 5:v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Rahman R, Asombang AW and Ibdah JA: Characteristics of gastric cancer in Asia. World J Gastroenterol. 20:4483–4490. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Kang JI, Chung HC, Jeung HC, Kim SJ, An SK and Namkoong K: FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective study. Psychoneuroendocrinology. 37:1569–1576. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Choi J, Kim SG, Im JP, Kim JS and Jung HC: Long-term clinical outcomes of endoscopic resection for early gastric cancer. Surg Endosc. 29:1223–1230. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L and Sturgeon C: Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 134:2513–2522. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Jin Z, Jiang W and Wang L: Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). Oncol Lett. 9:1502–1508. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Dellière S and Cynober L: Is transthyretin a good marker of nutritional status? Clin Nutr. 36:364–370. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Shimura T, Shibata M, Gonda K, Okayama H, Saito M, Momma T, Ohki S and Kono K: Serum transthyretin level is associated with prognosis of patients with gastric cancer. J Surg Res. 227:145–150. 2018. View Article : Google Scholar : PubMed/NCBI

27 

Su WP, Sun LN, Yang SL, Zhao H, Zeng TY, Wu WZ and Wang D: Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro. J Biochem Mol Toxicol. 32:e221582018. View Article : Google Scholar

28 

Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 12:297–304. 2001. View Article : Google Scholar : PubMed/NCBI

29 

Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, Gholami G and Mehdizadeh J: The valuable role of measuring serum lipid profile in cancer progression. Oman Med J. 30:353–357. 2015. View Article : Google Scholar : PubMed/NCBI

30 

Zhang T, Cui G, Feng WM, Shi QL, Cui J, Li XN, Wang QC and Shen H: Correlation analysis between glycolipids metabolism and clinicopathologic fe atures in patients with gastric cancer. Zhonghua Yi Xue Za Zhi. 96:2545–2547. 2016.(In Chinese). PubMed/NCBI

31 

Fujiya K, Kawamura T, Omae K, Makuuchi R, Irino T, Tokunaga M, Tanizawa Y, Bando E and Terashima M: Impact of malnutrition after gastrectomy for gastric cancer on long-term survival. Ann Surg Oncol. 25:974–983. 2018. View Article : Google Scholar : PubMed/NCBI

32 

Sun Y, Zhang J, Guo F, Zhao W, Zhan Y, Liu C, Fan Y and Wang J: Identification of apolipoprotein C-I peptides as a potential biomarker and its biological roles in breast cancer. Med Sci Monit. 22:1152–1160. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Huang D, Yuan W, Li H, Li S, Chen Z and Yang H: Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis. Exp Ther Med. 16:1850–1858. 2018.PubMed/NCBI

34 

Park J, Lee E, Park KJ, Park HD, Kim JW, Woo HI, Lee KH, Lee KT, Lee JK, Park JO, et al: Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Oncotarget. 8:42761–42771. 2017.PubMed/NCBI

35 

Ahn HS, Shin YS, Park PJ, Kang KN, Kim Y, Lee HJ, Yang HK and Kim CW: Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer. 106:733–739. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2019
Volume 17 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, M., Wang, J., & Jiang, H. (2019). Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer. Oncology Letters, 17, 3227-3232. https://doi.org/10.3892/ol.2019.9957
MLA
Wang, M., Wang, J., Jiang, H."Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer". Oncology Letters 17.3 (2019): 3227-3232.
Chicago
Wang, M., Wang, J., Jiang, H."Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer". Oncology Letters 17, no. 3 (2019): 3227-3232. https://doi.org/10.3892/ol.2019.9957